Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Glucagon-like peptide 1 receptor agonists (GLP1-RAs) did not increase thyroid cancer risk compared to dipeptidyl peptidase-4 inhibitors (DPP-4is) in type 2 diabetes patients. This study provides short-term safety reassurance for GLP1-RA use.
Area Of Science
- Endocrinology
- Oncology
- Pharmacology
Background
- Conflicting evidence exists regarding the association between glucagon-like peptide 1 receptor agonists (GLP1-RAs) and thyroid cancer risk.
- Type 2 diabetes patients are often prescribed these medications, necessitating safety evaluations.
Purpose Of The Study
- To investigate the association between GLP1-RA use and thyroid cancer risk compared to dipeptidyl peptidase-4 inhibitors (DPP-4is).
- To assess the short-term safety profile of GLP1-RAs concerning thyroid cancer incidence.
Main Methods
- A multisite cohort study and meta-analysis using six population-based databases (2007-2023).
- Cox regression models with propensity score weighting were used to compare thyroid cancer risk between GLP1-RA and DPP-4i users.
- Pooled hazard ratios (HR) and 95% confidence intervals (CIs) were calculated.
Main Results
- The study included 98,147 GLP1-RA users and 2,488,303 DPP-4i users with a median follow-up of 1.8–3.0 years.
- GLP1-RA use was not associated with an increased risk of thyroid cancer (pooled weighted HR 0.81, CI 0.59–1.12).
- No increased risk was observed with increasing cumulative GLP1-RA dose.
Conclusions
- This large, multisite study found no evidence of increased thyroid cancer risk with short-term GLP1-RA use in type 2 diabetes patients.
- Findings offer reassurance for the short-term safety of GLP1-RAs.
- Long-term safety data is still insufficient due to limited follow-up duration.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...